A	O
Novel	O
Potent	O
Anticancer	B:C0003392
Compound	I:C0003392
Optimized	O
from	O
a	O
Natural	O
Oridonin	O
Scaffold	O
Induces	O
Apoptosis	O
and	O
Cell	O
Cycle	I:C1155873
Arrest	I:C1155873
through	O
the	O
Mitochondrial	O
Pathway	I:C1513340

A	O
Novel	O
Potent	O
Anticancer	O
Compound	I:C0003392
Optimized	O
from	O
a	O
Natural	O
Oridonin	B:C0069639
Scaffold	O
Induces	O
Apoptosis	O
and	O
Cell	O
Cycle	I:C1155873
Arrest	I:C1155873
through	O
the	O
Mitochondrial	O
Pathway	I:C1513340

A	O
Novel	O
Potent	O
Anticancer	O
Compound	I:C0003392
Optimized	O
from	O
a	O
Natural	O
Oridonin	O
Scaffold	O
Induces	O
Apoptosis	B:C0162638
and	O
Cell	O
Cycle	I:C1155873
Arrest	I:C1155873
through	O
the	O
Mitochondrial	O
Pathway	I:C1513340

A	O
Novel	O
Potent	O
Anticancer	O
Compound	I:C0003392
Optimized	O
from	O
a	O
Natural	O
Oridonin	O
Scaffold	O
Induces	O
Apoptosis	O
and	O
Cell	B:C1155873
Cycle	I:C1155873
Arrest	I:C1155873
through	O
the	O
Mitochondrial	O
Pathway	I:C1513340

A	O
Novel	O
Potent	O
Anticancer	O
Compound	I:C0003392
Optimized	O
from	O
a	O
Natural	O
Oridonin	O
Scaffold	O
Induces	O
Apoptosis	O
and	O
Cell	O
Cycle	I:C1155873
Arrest	I:C1155873
through	O
the	O
Mitochondrial	B:C1513340
Pathway	I:C1513340

The	O
cytotoxicity	B:C0596402
of	O
the	O
natural	O
ent	O
-	I:C1254351
kaurene	I:C1254351
diterpenoid	I:C1254351
,	O
oridonin	O
,	O
has	O
been	O
extensively	O
studied	O
.	O

The	O
cytotoxicity	O
of	O
the	O
natural	O
ent	B:C1254351
-	I:C1254351
kaurene	I:C1254351
diterpenoid	I:C1254351
,	O
oridonin	O
,	O
has	O
been	O
extensively	O
studied	O
.	O

The	O
cytotoxicity	O
of	O
the	O
natural	O
ent	O
-	I:C1254351
kaurene	I:C1254351
diterpenoid	I:C1254351
,	O
oridonin	B:C0069639
,	O
has	O
been	O
extensively	O
studied	O
.	O

However	O
,	O
the	O
application	O
of	O
oridonin	B:C0069639
for	O
cancer	O
therapy	I:C0920425
was	O
hampered	O
primarily	O
by	O
its	O
moderate	O
potency	O
.	O

However	O
,	O
the	O
application	O
of	O
oridonin	O
for	O
cancer	B:C0920425
therapy	I:C0920425
was	O
hampered	O
primarily	O
by	O
its	O
moderate	O
potency	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	B:C0069639
A-ring	O
modified	I:C0002776
analogues	I:C0002776
,	I:C0002776
and	I:C0002776
their	I:C0002776
derivatives	I:C0002776
bearing	O
various	O
substituents	O
on	O
14	O
-	O
OH	O
position	O
,	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
anticancer	O
efficacy	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	O
A-ring	B:C0002776
modified	I:C0002776
analogues	I:C0002776
,	I:C0002776
and	I:C0002776
their	I:C0002776
derivatives	I:C0002776
bearing	O
various	O
substituents	O
on	O
14	O
-	O
OH	O
position	O
,	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
anticancer	O
efficacy	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	O
A-ring	O
modified	I:C0002776
analogues	I:C0002776
,	I:C0002776
and	I:C0002776
their	I:C0002776
derivatives	I:C0002776
bearing	O
various	O
substituents	O
on	O
14	O
-	O
OH	O
position	O
,	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	B:C0220825
for	O
anticancer	O
efficacy	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	O
A-ring	O
modified	I:C0002776
analogues	I:C0002776
,	I:C0002776
and	I:C0002776
their	I:C0002776
derivatives	I:C0002776
bearing	O
various	O
substituents	O
on	O
14	O
-	O
OH	O
position	O
,	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
anticancer	B:C0003392
efficacy	O
.	O

Some	O
of	O
the	O
derivatives	B:C0243072
were	O
significantly	O
more	O
potent	O
than	O
oridonin	O
against	O
both	O
drug	O
-	O
sensitive	O
and	O
drug	O
-	I:C0013203
resistant	I:C0013203
cancer	O
cells	I:C0334227
.	O

Some	O
of	O
the	O
derivatives	O
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B:C0069639
against	O
both	O
drug	O
-	O
sensitive	O
and	O
drug	O
-	I:C0013203
resistant	I:C0013203
cancer	O
cells	I:C0334227
.	O

Some	O
of	O
the	O
derivatives	O
were	O
significantly	O
more	O
potent	O
than	O
oridonin	O
against	O
both	O
drug	B:C1254351
-	O
sensitive	O
and	O
drug	O
-	I:C0013203
resistant	I:C0013203
cancer	O
cells	I:C0334227
.	O

Some	O
of	O
the	O
derivatives	O
were	O
significantly	O
more	O
potent	O
than	O
oridonin	O
against	O
both	O
drug	O
-	O
sensitive	O
and	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
cancer	O
cells	I:C0334227
.	O

Some	O
of	O
the	O
derivatives	O
were	O
significantly	O
more	O
potent	O
than	O
oridonin	O
against	O
both	O
drug	O
-	O
sensitive	O
and	O
drug	O
-	I:C0013203
resistant	I:C0013203
cancer	B:C0334227
cells	I:C0334227
.	O

The	O
most	O
potent	O
compound	B:C0003392
,	I:C0003392
13	I:C0003392
p	I:C0003392
,	O
was	O
200	O
-	O
fold	O
more	O
efficacious	O
than	O
oridonin	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cancer	I:C0596890
cells	I:C0596890
.	O

The	O
most	O
potent	O
compound	O
,	I:C0003392
13	I:C0003392
p	I:C0003392
,	O
was	O
200	O
-	O
fold	O
more	O
efficacious	O
than	O
oridonin	B:C0069639
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cancer	I:C0596890
cells	I:C0596890
.	O

The	O
most	O
potent	O
compound	O
,	I:C0003392
13	I:C0003392
p	I:C0003392
,	O
was	O
200	O
-	O
fold	O
more	O
efficacious	O
than	O
oridonin	O
in	O
MCF	B:C0596890
-	I:C0596890
7	I:C0596890
cancer	I:C0596890
cells	I:C0596890
.	O

Furthermore	O
,	O
13	B:C0003392
p	I:C0003392
induced	O
apoptosis	O
and	O
cell	O
cycle	I:C1155873
arrest	I:C1155873
at	O
the	O
G2	O
/	I:C1517347
M	I:C1517347
phase	I:C1517347
.	O

Furthermore	O
,	O
13	O
p	I:C0003392
induced	O
apoptosis	B:C0162638
and	O
cell	O
cycle	I:C1155873
arrest	I:C1155873
at	O
the	O
G2	O
/	I:C1517347
M	I:C1517347
phase	I:C1517347
.	O

Furthermore	O
,	O
13	O
p	I:C0003392
induced	O
apoptosis	O
and	O
cell	B:C1155873
cycle	I:C1155873
arrest	I:C1155873
at	O
the	O
G2	O
/	I:C1517347
M	I:C1517347
phase	I:C1517347
.	O

Furthermore	O
,	O
13	O
p	I:C0003392
induced	O
apoptosis	O
and	O
cell	O
cycle	I:C1155873
arrest	I:C1155873
at	O
the	O
G2	B:C1517347
/	I:C1517347
M	I:C1517347
phase	I:C1517347
.	O

A	O
decrease	O
in	O
mitochondrial	B:C1720920
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	B:C0219474
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	B:C4290004
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	B:C0597304
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	B:C0596890
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	B:C0087111
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	B:C0003392
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	B:C1513340
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	B:C0003392
p	I:C0003392
-	O
mediated	O
apoptosis	O
.	O

A	O
decrease	O
in	O
mitochondrial	O
membrane	I:C1720920
potential	I:C1720920
and	O
an	O
increase	O
in	O
Bax	O
/	I:C0219474
Bcl	I:C0219474
-	I:C0219474
2	I:C0219474
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase	I:C4290004
-	I:C4290004
3	I:C4290004
cleavage	O
,	O
were	O
observed	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
after	O
treatment	O
with	O
13	O
p	I:C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	I:C1513340
was	O
involved	O
in	O
the	O
13	O
p	I:C0003392
-	O
mediated	O
apoptosis	B:C0162638
.	O

Moreover	O
,	O
13	B:C0003392
p	I:C0003392
significantly	O
inhibited	O
tumor	O
growth	O
in	O
mouse	O
xenograft	O
models	I:C1520166
and	O
had	O
no	O
observable	I:C0857329
toxic	I:C0857329
effect	I:C0857329
.	O

Moreover	O
,	O
13	O
p	I:C0003392
significantly	O
inhibited	O
tumor	O
growth	O
in	O
mouse	B:C0025929
xenograft	O
models	I:C1520166
and	O
had	O
no	O
observable	I:C0857329
toxic	I:C0857329
effect	I:C0857329
.	O

Moreover	O
,	O
13	O
p	I:C0003392
significantly	O
inhibited	O
tumor	O
growth	O
in	O
mouse	O
xenograft	B:C1520166
models	I:C1520166
and	O
had	O
no	O
observable	I:C0857329
toxic	I:C0857329
effect	I:C0857329
.	O

Moreover	O
,	O
13	O
p	I:C0003392
significantly	O
inhibited	O
tumor	O
growth	O
in	O
mouse	O
xenograft	O
models	I:C1520166
and	O
had	O
no	B:C0857329
observable	I:C0857329
toxic	I:C0857329
effect	I:C0857329
.	O

